Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
MacroGenics, Inc. is a U.S.-based biotechnology company focused on the discovery and development of antibody-based therapeutics for the treatment of cancer. The company operates within the biopharmaceutical and oncology therapeutics industries, with a particular emphasis on immuno-oncology. Its core capabilities center on proprietary antibody engineering technologies designed to modulate immune responses and target tumor cells.
The company’s primary revenue drivers historically include clinical-stage drug development programs, collaboration and license agreements, and milestone payments from strategic partners. MacroGenics serves oncologists, healthcare providers, and patients primarily through clinical development pathways rather than direct commercial sales. Founded in 2000, the company built its platform around Fc engineering and bispecific antibody technologies and transitioned from a research-focused organization to a clinical-stage biotechnology company, culminating in its initial public offering in 2013.
Business Operations
MacroGenics operates as a single-reportable-segment biotechnology company, with operations focused on research, preclinical development, and clinical trials. Its pipeline is centered on antibody-based oncology candidates, including monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. Key proprietary technology platforms include Fc Optimization and Dual-Affinity Re-Targeting (DART) molecules, which are designed to enhance immune activation or improve tumor targeting.
The company conducts clinical trials primarily in the United States, with additional international trial sites as needed. MacroGenics does not manufacture products at commercial scale and relies on third-party contract manufacturers and research organizations. It has historically entered into strategic collaborations with larger pharmaceutical companies for co-development, regional rights, or out-licensing of certain assets, while retaining internal control over its core research and early-stage development programs.
Strategic Position & Investments
MacroGenics’ strategy emphasizes advancing a focused oncology pipeline while selectively partnering assets to manage capital requirements and development risk. Growth initiatives have centered on progressing internally developed candidates through mid- to late-stage clinical trials and leveraging its antibody engineering platforms to generate new therapeutic candidates.
The company has made targeted investments in its clinical portfolio rather than pursuing large-scale acquisitions. Notable programs have included checkpoint inhibitors and immune-modulating antibodies developed internally or in collaboration with partners. MacroGenics continues to explore emerging areas within immuno-oncology, including combination therapies and next-generation antibody constructs, while periodically reprioritizing its pipeline based on clinical data and capital allocation considerations.
Geographic Footprint
MacroGenics is headquartered in Rockville, Maryland, and its operations are primarily concentrated in the United States. Research, development, and corporate functions are largely centralized at its Maryland facilities, supporting laboratory research and clinical program management.
Internationally, the company’s presence is primarily indirect, achieved through global clinical trial sites and partnerships with non-U.S. pharmaceutical companies. While MacroGenics does not maintain extensive overseas infrastructure, its development programs and collaborations provide it with exposure to Europe and parts of Asia through multinational clinical studies and licensing arrangements.
Leadership & Governance
MacroGenics was founded by scientists with expertise in antibody engineering, and its leadership structure reflects a strong emphasis on scientific and clinical development. The company is led by executives with experience across biotechnology research, clinical development, and public company governance. Its leadership philosophy emphasizes disciplined capital management, data-driven decision-making, and leveraging proprietary technology to create differentiated oncology therapies.
Key executives include:
- Scott Koenig – President and Chief Executive Officer
- James Karrels – Chief Financial Officer
- Anna K. Browne – Chief Operating Officer
- John P. Leonard – Chief Scientific Officer
- Diane M. Jelinek – Chief Medical Officer